Can broad Borrelia antibody reactivity reflect cross-reactivity rather than multiple infections?

In an 83-year-old man, a broad Borrelia antibody pattern should be interpreted as evidence of immune reactivity—not, on its own, evidence that multiple Borrelia infections are present concurrently.

Cross-reactivity and diagnostic meaning

• Conserved Borrelia proteins can generate antibodies that bind homologous antigens across distinct genospecies. In one Bdr-protein study, cross-reactive bands occurred among B. burgdorferi, B. garinii, B. afzelii, B. hermsii, and B. turicatae; 24 of 47 Lyme-patient sera recognized at least one Bdr protein.
• Conserved BmpA epitopes are recognized across B. burgdorferi, B. afzelii, and B. garinii, and an OspB monoclonal antibody recognized a conserved epitope across diverse isolates. Thus, multi-antigen or multispecies reactivity can result from a single antibody response directed at shared epitopes.
• The effect is antigen-specific. Conserved FlaB/p41 epitopes may also react with syphilis sera, while antibodies to relapsing-fever organisms can produce Lyme EIA or immunoblot positivity. EBV and rheumatoid arthritis can also contribute to false-positive serology.

Mechanistic and clinical implications

• Cross-reactive binding reflects antigenic conservation rather than proof that every reactive species is infecting the patient. Variable antigens, such as VlsE/Vmp proteins, may behave differently from conserved structural proteins.
• Antibodies can persist for years after prior exposure; therefore, even validated Lyme serology does not establish active infection or distinguish a remote infection from current disease.
• Reports of antibodies to multiple Lyme genospecies despite PCR detection of only one organism further show that broad seroreactivity is not species-level confirmation.

Bottom line

• Multispecies or multi-antigen Borrelia seroreactivity is biologically expected from conserved-protein cross-reactivity and cannot prove simultaneous infections. Concurrent infection requires independent, appropriately timed, species-discriminating confirmation from clinically relevant specimens; serology alone is insufficient.